Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-08-28Clinical Trial Update: Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors [Phase 1]
A Phase 1 clinical trial evaluating the KRAS G12D-targeting agent RMC-9805 is currently recruiting for multiple solid tumor indications incl…
-
EMA approval · 2025-08-27EMA Authorised: Tabrecta (capmatinib dihydrochloride monohydrate) — Novartis Europharm Limited
The EMA authorised Tabrecta (capmatinib dihydrochloride monohydrate) for non-small cell lung cancer. Novartis Europharm Limited is the marke…
-
CLINICAL_TRIALS trial_result · 2025-08-27Clinical Trial Update: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor [Phase 2]
Phase 2 trial evaluating atezolizumab plus tiragolumab in patients with non-small cell lung cancer or advanced solid tumors who previously r…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Gavo-cel (TC-210), a mesothelin-targeted therapy, in patients with advanced mesothelin-expressing cancer…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Clinical trial update for cemiplimab in combination with platinum-doublet chemotherapy as first-line treatment for advanced non-small cell l…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-27Clinical Trial Update: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]
A Phase 1/2 study of TC-510 from TCR2 Therapeutics in mesothelin-expressing cancers is active but not recruiting, spanning multiple indicati…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer [Phase 1]
Phase 1 clinical trial update for YL202 in patients with non-small cell lung cancer and breast cancer; the study is currently active but not…
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer [Phase 2]
This update reports results from a Phase 2 study evaluating PD-L1 positive non-small cell lung cancer treated with immunotherapy as monother…
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) [Phase 3]
A Phase 3 trial comparing the pembrolizumab/vibostolimab coformulation MK-7684A with pembrolizumab monotherapy in PD-L1–positive metastatic …
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009) [NA]
This clinical trial entry describes a study evaluating sentinel lymph node dissection (SLND) versus no SLND in cT1 invasive lung adenocarcin…
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC [Phase 2]
A Phase 2 trial evaluating the combination of iparomlimab and tuvonralimab with chemotherapy to convert initially unresectable Stage III non…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC [Phase 2]
Phase 2 study evaluating CAN-2409 plus a prodrug with standard immune checkpoint inhibitor therapy for stage III/IV non-small cell lung canc…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial investigating metabolic biomarkers to predict response to neoadjuvant immunotherapy in Non-Small Cell Lung Cancer; study statu…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Guardant Health's ORACLE trial is currently recruiting to evaluate residual cancer using a liquid biopsy across multiple cancer types.
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography [NA]
Clinical trial update reporting results of dexamethasone effects in patients with refractory non-small cell lung cancer, assessed using FLT …
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors [Phase 1]
This is a Phase 1 clinical trial update for BL-M09D1 in patients with locally advanced or metastatic non-small cell lung cancer and other so…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
The SIBYL study investigates therapy response assessment using liquid biopsy in cancer patients. The trial is currently recruiting and inclu…
-
CLINICAL_TRIALS withdrawal · 2025-08-22Clinical Trial Update: Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating Luveltamab Tazevibulin in adults with advanced or metastatic non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Primary Radiotherapy In MEtastatic Lung Cancer [Phase 3]
Phase 3 clinical trial evaluating primary radiotherapy for metastatic non-small cell lung cancer; trial status is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-08-21Clinical Trial Update: A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung [Phase 1]
Phase I/Ib study evaluating the MEK1/2 inhibitor binimetinib (MEK162) in combination with carboplatin and pemetrexed in patients with non-sq…
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) [Phase 2]
A Phase 2 trial is evaluating the cancer vaccine BNT116 in combination with cemiplimab for adults with advanced non-small cell lung cancer; …
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC [Phase 2]
Phase 2 clinical trial update evaluating QL1706 with bevacizumab, with or without chemotherapy, in patients with non-squamous non-small cell…
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial update reports results from evaluating the combination of sirolimus and auranofin in patients with advanced…
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) [Phase 1, Phase 2]
Phase 1/2 trial results for GLIMMER-01, a bi-sialidase fusion protein from Palleon, tested across multiple solid tumors with results posted …
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors [Phase 1]
This Phase 1 trial assesses safety, tolerability, and preliminary efficacy of lomvastomig, a PD-1/TIM-3 bispecific antibody, in adults with …